Abstract:
PURPOSE: A catalyzed resolution method of racemic cis-1,3-dioxolane derivatives is provided, thereby effectively separating racemic cis-1,3-dioxolane derivatives which is useful as an intermediate used for preparing itraconazole and ketoconazole. CONSTITUTION: The catalyzed resolution method of racemic cis-1,3-dioxolane derivatives represented by formula (1) comprises hydrolysis of racemic cis-1,3-dioxolane derivatives using enzyme in a phosphate buffer solution at pH 6 to 9 and 20 to 60 deg. C to prepare pure cis-1,3-dioxolane derivatives of formulas (1a) and (1b), wherein R is CH2OH, COOH, COOR' or CH2OCOR'; R' is C1-C10 alkyl; the enzyme is Pseudomonas cepacia(PCL) or Candida antartica(CAL).
Abstract:
PURPOSE: Provided is prodigiosin isolated from culture broth of Serratia marcescens. The prodigiosin inhibits specifically immunogenecity of T cell and is used in immunosuppresive drug. CONSTITUTION: A Prodigiosin isolated from culture broth of Serratia marcescens B-1231 (KCTC 0386BP) is represented by the formula (I). The Prodigiosin is prepared by the following steps of: (a) cultivating Serratia marcescens B-1231 (KCTC 0386BP) in a medium comprised of soluble starch of 1%, glucose of 0.25, ammonium sulfate of 0.1%, potassium phosphate of 0.1%, magnesium sulfate- septuple crystal solution of 0.05%, calcium chloride of 0.1 %, sodium chloride of 0.3% at pH value of 7 and temperature of 28 deg.C for 62 hours; (b) mixing them with adding ethyl acetate in a same amount, thereto for 30 minutes, to obtain organic solvent layer; (c) concentrating the mixture under reduced pressure, to obtain a red material; (d) isolating and purifying an active material therefrom; and (e) purifying it by silicagel thin layer chromatography.
Abstract:
PURPOSE: A catalyzed resolution method of racemic cis-1,3-dioxolane derivatives is provided, thereby effectively separating racemic cis-1,3-dioxolane derivatives which is useful as an intermediate used for preparing itraconazole and ketoconazole. CONSTITUTION: The catalyzed resolution method of racemic cis-1,3-dioxolane derivatives represented by formula (1) comprises hydrolysis of racemic cis-1,3-dioxolane derivatives using enzyme in a phosphate buffer solution at pH 6 to 9 and 20 to 60 deg. C to prepare pure cis-1,3-dioxolane derivatives of formulas (1a) and (1b), wherein R is CH2OH, COOH, COOR' or CH2OCOR'; R' is C1-C10 alkyl; the enzyme is Pseudomonas cepacia(PCL) or Candida antartica(CAL).
Abstract:
PURPOSE: A separating method of a single isomer from the ketorolac of the racemic body is provided, thereby separating the high purity of a single isomer form ketorolac. CONSTITUTION: The separating method of a single isomer from the ketorolac of the racemic body comprises the steps of: reaction of the ketorolac of the racemic body represented by formula(1) with alcohol compounds in the presence of Candida antartica lipase B; and separation of (-)-isomer from the reaction mixture by absorption, wherein the alcohol compounds are C3 to C20 alcohols; the amount of the Candida antartica lipase B is 10 to 150 wt.%; and the reaction temperature is 20 to 70 deg. C.
Abstract:
본 발명은 세라시아 마르세센스(Serratia Marcescens)의 배양액에서 분리한 프로디지오신 (Prodigiosin)의 면역억제 물질로서의 신규한 용도에 관한 것으로 조직 및 장기이식 등의 면역억제를 필요로하는 치료분야에서의 면역억제약물로서의 이용 및 이들의 기초기전연구를 위한 면역억제 약물로서의 이용 나아가 프로디지오신의 면역억제효과를 응용한 면역학 기초연구를 위한 면역억제 시료로서의 이용에 관한 것이다.
Abstract:
PURPOSE: Disclosed are a porous catalyst composed of pillard silica and metal oxide and a preparation method of ε-caprolactam from cyclohexanone oxime. CONSTITUTION: The porous catalyst is mainly composed of a pillard silica and a metal oxide. The sodium ion (Na+) on pillard silica is substituted with hydrogen ion (H+) of inorganic acid solution and a spacing width of pillard silica expands to 20 - 30 Å by using a long chained amine compound. And then metal oxide compounds are added in the spacing interval of the pillared silica. The added content of metal oxide is optimally 2 - 10 wt% and the surface area is 100 - 300 m2/g. The pillared silica is precipitated from kanemite, kenyaite, magadite, illite, octosilicate and Ta2O5, Nb2O5, TiO2 or SiO2 are used as metal oxides.
Abstract translation:目的:公开了由二氧化硅和金属氧化物组成的多孔催化剂和由环己酮肟制备的ε-己内酰胺的制备方法。 构成:多孔催化剂主要由二氧化硅和金属氧化物组成。 使用长链胺化合物,将二氧化硅上的钠离子(Na +)用无机酸溶液的氢离子(H +)代替,并将二氧化硅的间隔宽度扩大至20〜30。 然后在柱状二氧化硅的间隔间隔中加入金属氧化物。 金属氧化物的添加量最好为2〜10重量%,表面积为100〜300m2 / g。 柱状二氧化硅从可卡因,肯尼亚,magadite,伊利石,八硅酸盐和Ta 2 O 5,Nb 2 O 5,TiO 2或SiO 2中析出用作金属氧化物。
Abstract:
PURPOSE: Provided are a process for preparing a zeolite catalyst and a process for preparing ε-caprolactam from cyclohexanone oxime in the presence of the zeolite catalyst by Beckmann conversion reaction. CONSTITUTION: The MFI and MEL type zeolite catalysts having a molar ratio of Si/Al being more than 500 is treated at 20-150 °C with 0.01-0.5 N by concentration of an acid selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, and acetic acid. The ε-caprolactam is prepared from cyclohexanone oxime by Beckman conversion reaction at 250-400 °C in the presence of the acid treated zeolite catalyst.